Cargando…

Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials

The first-generation, live attenuated rotavirus (RV) vaccines, such as RotaTeq and Rotarix, were successful in reducing the number of RV-induced acute gastroenteritis (AGE) and child deaths globally. However, the low efficacy of these first-generation oral vaccines, coupled with safety concerns, req...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoja, Zabihollah, Jalilvand, Somayeh, Latifi, Tayebeh, Roohvand, Farzin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923333/
https://www.ncbi.nlm.nih.gov/pubmed/35292854
http://dx.doi.org/10.1007/s00705-022-05407-9
_version_ 1784669658485358592
author Shoja, Zabihollah
Jalilvand, Somayeh
Latifi, Tayebeh
Roohvand, Farzin
author_facet Shoja, Zabihollah
Jalilvand, Somayeh
Latifi, Tayebeh
Roohvand, Farzin
author_sort Shoja, Zabihollah
collection PubMed
description The first-generation, live attenuated rotavirus (RV) vaccines, such as RotaTeq and Rotarix, were successful in reducing the number of RV-induced acute gastroenteritis (AGE) and child deaths globally. However, the low efficacy of these first-generation oral vaccines, coupled with safety concerns, required development of improved RV vaccines. The highly conserved structural protein VP6 is highly immunogenic, and it can generate self-assembled nano-sized structures, including tubes and spheres (virus-like particles; VLPs). Amongst the RV proteins, only VP6 shows these features. Interestingly, VP6-assembled structures, in addition to being highly immunogenic, have several other useful characteristics that could allow them to be used as adjuvants, immunological carriers, and drug-delivery vehicles as well as acting a scaffold for production of valuable nano-biomaterials. This review provides an overview of the self-assembled nano-sized structures of VP6-tubes/VLPs and their various functions.
format Online
Article
Text
id pubmed-8923333
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-89233332022-03-15 Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials Shoja, Zabihollah Jalilvand, Somayeh Latifi, Tayebeh Roohvand, Farzin Arch Virol Review The first-generation, live attenuated rotavirus (RV) vaccines, such as RotaTeq and Rotarix, were successful in reducing the number of RV-induced acute gastroenteritis (AGE) and child deaths globally. However, the low efficacy of these first-generation oral vaccines, coupled with safety concerns, required development of improved RV vaccines. The highly conserved structural protein VP6 is highly immunogenic, and it can generate self-assembled nano-sized structures, including tubes and spheres (virus-like particles; VLPs). Amongst the RV proteins, only VP6 shows these features. Interestingly, VP6-assembled structures, in addition to being highly immunogenic, have several other useful characteristics that could allow them to be used as adjuvants, immunological carriers, and drug-delivery vehicles as well as acting a scaffold for production of valuable nano-biomaterials. This review provides an overview of the self-assembled nano-sized structures of VP6-tubes/VLPs and their various functions. Springer Vienna 2022-03-15 2022 /pmc/articles/PMC8923333/ /pubmed/35292854 http://dx.doi.org/10.1007/s00705-022-05407-9 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review
Shoja, Zabihollah
Jalilvand, Somayeh
Latifi, Tayebeh
Roohvand, Farzin
Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials
title Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials
title_full Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials
title_fullStr Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials
title_full_unstemmed Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials
title_short Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials
title_sort rotavirus vp6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923333/
https://www.ncbi.nlm.nih.gov/pubmed/35292854
http://dx.doi.org/10.1007/s00705-022-05407-9
work_keys_str_mv AT shojazabihollah rotavirusvp6involvementinimmunogenicityadjuvantactivityanduseasavectorforheterologouspeptidesdrugdeliveryandproductionofnanobiomaterials
AT jalilvandsomayeh rotavirusvp6involvementinimmunogenicityadjuvantactivityanduseasavectorforheterologouspeptidesdrugdeliveryandproductionofnanobiomaterials
AT latifitayebeh rotavirusvp6involvementinimmunogenicityadjuvantactivityanduseasavectorforheterologouspeptidesdrugdeliveryandproductionofnanobiomaterials
AT roohvandfarzin rotavirusvp6involvementinimmunogenicityadjuvantactivityanduseasavectorforheterologouspeptidesdrugdeliveryandproductionofnanobiomaterials